Caroline Vu

Special Counsel
Full contact info

Experience

Kite Pharma Announces Clinical Collaboration with Humanigen

August 21, 2020

Cooley advised Kite Pharma, a Gilead company, dedicated to developing active immunotherapies, in the formation of a clinical collaboration with Humanigen, Inc. to conduct a Phase ½ study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The goal of this collaboration is to determine the effect of lenzilumab on the clinical profile of Yescarta. Financial terms were not disclosed. Cooley special counsel Caroline Vu advised Kite.

Related contacts

Caroline Vu
Special Counsel, Palo Alto

Related Practices & Industries

Kite Pharma Announces Clinical Collaboration with Kiniksa Pharmaceuticals

August 21, 2020

Cooley advised Kite Pharma, a Gilead company, dedicated to developing active immunotherapies, in its clinical collaboration with Kiniksa Pharmaceuticals to conduct a Phase 2, multicenter study of mavrilimumab, an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma. The goal of this collaboration is to determine the effect of mavrilimumab on the clinical profile of Yescarta. Financial terms were not disclosed. Cooley special counsel Caroline Vu advised Kite.

Related contacts

Caroline Vu
Special Counsel, Palo Alto

Related Practices & Industries

Xyphos Biosciences in its Research Collaboration and License Agreement with Parker Institute for Cancer Immunotherapy

September 3, 2019

Admissions and credentials

California